Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More
AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT)
jumped 5.4% in the morning session after the company reported decent first-quarter 2025 results with revenue in line, although its organic revenue fell slightly short of Wall Street's estimates. EPS in the quarter beat slightly, while full-year EPS guidance met expectations. The full-year sales outlook was also maintained, which was encouraging despite the uncertain macro backdrop.
U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip export restrictions to China.
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4% year on year to $10.36 billion. Its non-GAAP profit of $1.09 per share was 1.7% above analysts’ consensus estimates.
